POLITICS โ Johor MB launches Semarak Maghrib and Isyak programme to boost mosque attendance (Malaymail)WORLD โ MRT Corp awards RM3.03b Penang Mutiara LRT systems contract to MRCB-Theta Edge JV (Malaymail)WORLD โ SNAPSHOT | PM's aide is Ampang parliamentary coordinator; IGP vows to boost aviation security (Malaysiakini)WORLD โ Polis serbu sindiket bungkus cecair vape di kondominium (Utusan)WORLD โ Pengurusan banjir perlu ditangani pendekatan proaktif (Utusan)WORLD โ 'Parti Lipas' berpotensi gugat sokongan Modi (Utusan)WORLD โ Bantuan ke Gaza tidak melalui pintu sempadan (Utusan)WORLD โ DUN Selangor: Pengurusan fatwa diselaras struktur peringkat kebangsaan (Utusan)POLITICS โ Johor MB launches Semarak Maghrib and Isyak programme to boost mosque attendance (Malaymail)WORLD โ MRT Corp awards RM3.03b Penang Mutiara LRT systems contract to MRCB-Theta Edge JV (Malaymail)WORLD โ SNAPSHOT | PM's aide is Ampang parliamentary coordinator; IGP vows to boost aviation security (Malaysiakini)WORLD โ Polis serbu sindiket bungkus cecair vape di kondominium (Utusan)WORLD โ Pengurusan banjir perlu ditangani pendekatan proaktif (Utusan)WORLD โ 'Parti Lipas' berpotensi gugat sokongan Modi (Utusan)WORLD โ Bantuan ke Gaza tidak melalui pintu sempadan (Utusan)WORLD โ DUN Selangor: Pengurusan fatwa diselaras struktur peringkat kebangsaan (Utusan)
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2ฮฑ-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
SAN FRANCISCO and SUZHOU, China, Aug. 6, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major... The post Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2ฮฑ-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China appeared first on Kosmo Digital.
Kosmo Kosmo ยท Wire Report ยท 10 hours ago ยท 1 min read
Image via wire syndication ยท Kosmo
WIRE โ
SAN FRANCISCO and SUZHOU, China, Aug. 6, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major... The post Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2ฮฑ-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China appeared first on Kosmo Digital.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.